Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists

CVS Health, the largest U.S. pharmacy benefit manager, has decided not to immediately add Gilead Sciences' new, highly effective HIV prevention drug, Yeztugo, to its commercial plans and Affordable Care Act formularies, citing clinical, financial, and regulatory factors. This move, despite Yeztugo's nearly 100% efficacy and its over $28,000 annual list price, poses a significant challenge to Gilead's ambitious U.S. insurer coverage targets and underscores the ongoing friction between drug manufacturers and PBMs over pricing and formulary inclusion for high-cost specialty pharmaceuticals, impacting market access and public health initiatives.

Analysis

CVS Health's decision to temporarily withhold coverage for Gilead Sciences' new HIV prevention drug, Yeztugo, on its commercial and ACA formularies represents a significant near-term obstacle to the drug's market penetration. As the largest U.S. pharmacy benefit manager (PBM), CVS's move, attributed to "clinical, financial, and regulatory factors," directly challenges Gilead's ability to meet its ambitious target of 75% U.S. insurer coverage by year-end. The core of the conflict appears to be the drug's high list price of over $28,000 annually, which triggers aggressive negotiation tactics from PBMs despite Yeztugo's proven near-100% efficacy. The situation highlights the immense pricing power wielded by the top three PBMs, which control approximately 70% of specialty drug prescriptions. While this is a setback, Gilead has secured coverage from key government payers, including the VA, Medicare, and major state Medicaid plans, providing some commercial leverage. However, the path to widespread commercial access remains uncertain, with UnitedHealth's OptumRX's upcoming review now a critical catalyst. Furthermore, regulatory ambiguity persists as Yeztugo is not yet included in the U.S. Preventive Services Task Force (USPSTF) recommendations, a key driver for mandatory insurer coverage, creating a potential political risk under the new HHS leadership.

Key Decisions for Investors

• Investors in Gilead (GILD) should view this as a significant near-term headwind and must closely monitor formulary decisions from other major PBMs like OptumRX (UNH) and Express Scripts (CI), as these will be critical determinants for Yeztugo's revenue trajectory.
• The standoff underscores the persistent negotiating power of PBMs in the U.S. healthcare system; this event may increase scrutiny on CVS's practices but reinforces its ability to manage specialty drug costs, a key tenet of its business model.
• Monitor any developments related to the U.S. Preventive Services Task Force (USPSTF), as a future recommendation for Yeztugo would mandate broad coverage without cost-sharing, effectively bypassing current PBM resistance and significantly de-risking the drug's commercial launch.